Table 2.
Pharmacokinetic properties of mefloquine in pregnant women and non-pregnant women
| Pregnant women (n = 24) | Non-pregnant women (n = 24) | P | |
|---|---|---|---|
| Body weight (kg) | 52.0 (46–69.5) | 52.8 (46.5–70.0) | 0.973 |
| Total dose (mg/kg) | 25.4 (18.99–28.70) | 25.1 (18.86–29.33) | 0.693 |
| No. points lambda | 11.0 (3–15) | 11.0 (3–14) | 0.991 |
| Cmax (ng/mL) | 1558 (625–2475) | 1392 (660–1864) | 0.283 |
| Cmax/dose [(ng/mL)/(mg/kg)] | 59.3 (24.38–105.90) | 57.5 (25.25–78.00) | 0.336 |
| Tmax (h) | 56.0 (50–240) | 60.0 (49–240) | 0.306 |
| CL/F (L/h) | 2.0 (0.93–3.94) | 2.4 (1.24–5.27) | 0.059 |
| CL/F (L/h/kg) | 0.04 (0.016–0.076) | 0.04 (0.024–0.108) | 0.083 |
| V/F (L) | 1036.0 (489.9–2,201.0) | 948.7 (674.1–2195.0) | 0.534 |
| V/F (L/kg) | 21.0 (8.67–42.73) | 17.3 (12.49–38.98) | 0.655 |
| t1/2 (h) | 390.2 (177.6–570.6) | 289.2 (200.0–394.7) | <0.001 |
| AUC0–LAST (h × ng/mL) | 544 500 (211 100–1 301 000) | 501 200 (118 400–960 000) | 0.258 |
| AUC0–∞ (h × ng/mL) | 656 700 (334 700–1 418 000) | 542 400 (250 600–1 066 000) | 0.059 |
| AUC0–∞/dose [(h × ng/mL)/(mg/kg)] | 25 690 (13 190–60 700) | 22 810 (9281–41 990) | 0.083 |
| Ext. AUC (%) | 12.5 (5.4–42.5) | 5.7 (1.2–56.5) | <0.001 |
No. points lambda, number of observations used in the log-linear regression in the terminal elimination phase; F, oral bioavailability; Ext. AUC, percentage of AUC0–∞ extrapolated from the last observation to infinity.
Values are presented as median (range).